Welcome to: Rimonabant Information Source (rimonabant and fda and today)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

He also called the 2-year safety data "encouraging". But he sounded a note of caution: "If you look at the weight-loss data, with 2 years the curves start to head up. And we all know that obesity is not only a 2-year issue .... We d really want to know what happens after 2 years. We want to post-marketing studies to see whether this effect is maintained long term. "Dr Gardin also various philosophical issues that are on the minds of many doctors who had contested the fury that followed the fen-phen (fenfluramine-phentermine) controversy. "Hypothetically, what if rimonabant is approved, the market, we have 5 million prescriptions, and we get all the wonderful positive effects described in the study - but it appears that one person per million dies in connection with the drugs, what should reasonable people do? Should they say that it is an acceptable risk-benefit ratio? Or should we deal with the way the previous anorexigens were treated with repressive measures? And who makes this decision? "said Dr.

Rimonabant Pricelist

Please wait while we load the price list
Early Phase 2 data published in April 2004 showed that inhibiting CETP with torcetrapib at 120 mg per day produced significant increases in HDL-C when given alone (46%), as well as in combination with Lipitor (61%). When the dosage of torcetrapib was increased to 240 mg per day, HDL-C increased by over 100%. However, patients taking 60 mg of torcetrapib with Lipitor also experienced an increase in systolic blood pressure, a drawback which may outweigh the benefit of raised HDL-C. It is currently estimated that Torcetrapib will be in the U. S.market in 2008. Rimonabant-Acomplia (discovered and developed by Sanofi-Aventis) is a CB1 endocannabinoid receptor antagonist. CB1 blockers act on the endocannabinoid system, a system controlling energy and nicotine dependence, reducing the overstimulation thought to lead to obesity and nicotine addiction.

The information was clear to conclude that the drug which can control the action of CB-1 receptor can also have control over appetite and urge for tobacco. Sanofi-Aventis of France the prominent drug manufacturer realized the significance of this fact and started its research with Rimonabant. These clinical trials with Rimonabant were basically focused on using Rimonabant as medication for cessation of smoking. During clinical trials the drug developers came across to know about the high efficacy of the Rimonabant as an appetite suppressor. Then rigorous clinical trials were conducted with the view of checking the feasibility and suitability of Rimonabant as an anti-obesity drug. The medication set the high standard and evolved a ray of hope for millions of obese across the globe.